SCHEMBL32677941

SCHEMBL32677941

O=C(C1CC1)[C@@H]1C[C@@H]2C=C[C@H]1N(C(=O)Oc1ccccc1)C2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
CHRNA7 P36544 1/20 0.43
HTR3A P46098 1/20 0.43
GAA P10253 1/20 0.39
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
AGTR2 P50052 2/20 0.36
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HTT P42858 1/20 0.35
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677942 1.00 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA
SCHEMBL32677926 0.87 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA
SCHEMBL32677927 0.87 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA
SCHEMBL32677917 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL32677918 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL32677920 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL32677922 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL32677914 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1GAANPC1RAB9A
SCHEMBL32677937 0.79 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA
SCHEMBL32677939 0.79 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055109-A1 IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS UNIV CALIFORNIA (US) 2026-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055109-A1 IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS HTR7, HTR3B, HTR3A SMN1; SMN2 982/4885ALDH1A1 1379/4885CHRNA7 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.